SG10201707763PA - FGF21 Mutants And Uses Thereof - Google Patents

FGF21 Mutants And Uses Thereof

Info

Publication number
SG10201707763PA
SG10201707763PA SG10201707763PA SG10201707763PA SG10201707763PA SG 10201707763P A SG10201707763P A SG 10201707763PA SG 10201707763P A SG10201707763P A SG 10201707763PA SG 10201707763P A SG10201707763P A SG 10201707763PA SG 10201707763P A SG10201707763P A SG 10201707763PA
Authority
SG
Singapore
Prior art keywords
fgf21 mutants
fgf21
mutants
Prior art date
Application number
SG10201707763PA
Inventor
Edward John Belouski
Murielle Marie Ellison
Agnes Eva Hamburger
Randy Ira Hecht
Yue-Sheng Li
Mark Leo Michaels
Jeonghoon Sun
Jing Xu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42455356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201707763P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG10201707763PA publication Critical patent/SG10201707763PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
SG10201707763PA 2009-05-05 2010-05-04 FGF21 Mutants And Uses Thereof SG10201707763PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17573609P 2009-05-05 2009-05-05
US28511809P 2009-12-09 2009-12-09

Publications (1)

Publication Number Publication Date
SG10201707763PA true SG10201707763PA (en) 2017-11-29

Family

ID=42455356

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2011080637A SG175861A1 (en) 2009-05-05 2010-05-04 Fgf21 mutants and uses thereof
SG10201707763PA SG10201707763PA (en) 2009-05-05 2010-05-04 FGF21 Mutants And Uses Thereof
SG10201402038WA SG10201402038WA (en) 2009-05-05 2010-05-04 FGF21 Mutants And Uses Thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2011080637A SG175861A1 (en) 2009-05-05 2010-05-04 Fgf21 mutants and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201402038WA SG10201402038WA (en) 2009-05-05 2010-05-04 FGF21 Mutants And Uses Thereof

Country Status (37)

Country Link
US (4) US8188040B2 (en)
EP (3) EP2427208B1 (en)
JP (1) JP5823954B2 (en)
KR (2) KR101860572B1 (en)
CN (2) CN107188950B (en)
AR (1) AR076541A1 (en)
AU (1) AU2010246108B2 (en)
BR (1) BRPI1011404B1 (en)
CA (1) CA2760196C (en)
CL (1) CL2011002768A1 (en)
CO (1) CO6470863A2 (en)
CR (1) CR20110639A (en)
DK (1) DK3248610T3 (en)
EA (1) EA021425B1 (en)
ES (2) ES2632742T3 (en)
FI (1) FI3248610T3 (en)
HK (1) HK1247134A1 (en)
HR (1) HRP20240135T1 (en)
HU (1) HUE065036T2 (en)
IL (2) IL215937A (en)
JO (1) JO3469B1 (en)
LT (1) LT3248610T (en)
MA (1) MA33716B1 (en)
MX (1) MX2011011709A (en)
MY (1) MY156542A (en)
NZ (1) NZ596037A (en)
PE (2) PE20160718A1 (en)
PH (1) PH12015502433B1 (en)
PL (1) PL3248610T3 (en)
PT (1) PT3248610T (en)
RS (1) RS65153B1 (en)
SG (3) SG175861A1 (en)
SI (1) SI3248610T1 (en)
TW (2) TWI436776B (en)
UY (2) UY32607A (en)
WO (1) WO2010129503A1 (en)
ZA (1) ZA201108371B (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
PE20120021A1 (en) 2008-10-10 2012-02-10 Amgen Inc MUTANTS FGF21
CN107188950B (en) 2009-05-05 2021-09-28 安姆根有限公司 FGF21 mutant and application thereof
MX2011011815A (en) * 2009-05-05 2012-01-27 Amgen Inc Fgf21 mutants and uses thereof.
EP2443145A1 (en) 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
EP2679234A3 (en) 2009-12-02 2014-04-23 Amgen Inc. Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
US20130116171A1 (en) 2010-04-16 2013-05-09 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
US20140189893A1 (en) * 2011-05-10 2014-07-03 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta klotho
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
JP2014526441A (en) * 2011-08-31 2014-10-06 アムジエン・インコーポレーテツド FGF21 for use in the treatment of type 1 diabetes
AU2015202304C1 (en) * 2011-09-26 2017-03-09 Novartis Ag Fusion proteins for treating metabolic disorders
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
US9006400B2 (en) 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
AR087973A1 (en) 2011-10-04 2014-04-30 Lilly Co Eli VARIATIONS OF FACTOR 21 GROWTH OF FIBROBLASTS
WO2013131091A1 (en) 2012-03-02 2013-09-06 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
NZ701573A (en) 2012-05-17 2017-04-28 Extend Biosciences Inc Carriers for improved drug delivery
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
TWI513705B (en) 2012-06-11 2015-12-21 Lilly Co Eli Fibroblast growth factor 21 proteins
CA2871656A1 (en) 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 variants
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (en) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Compositions and methods for the treatment of metabolic disorders and diseases
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
KR101993714B1 (en) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. Compositions and methods of use in treating metabolic disorders
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
EP3060238A4 (en) 2013-10-21 2017-06-07 Salk Institute for Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
JP6837840B2 (en) 2014-01-24 2021-03-10 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Binding protein and how to use it
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
AU2015236073B2 (en) 2014-03-25 2020-04-30 Regeneron Pharmaceuticals, Inc. FGF21 receptor agonists and uses thereof
CN103923207B (en) * 2014-04-08 2016-03-09 东北农业大学 A kind of preparation of FGF-21 mutant protein and the application in treatment non-alcoholic fatty liver disease thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
AP2016009663A0 (en) 2014-07-30 2016-12-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US10517929B2 (en) 2014-10-23 2019-12-31 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising FGF19 variants
TN2017000113A1 (en) 2014-10-31 2018-07-04 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
PL3236991T3 (en) 2014-12-23 2019-12-31 Novo Nordisk A/S Fgf21 derivatives and uses thereof
KR20160088656A (en) 2015-01-16 2016-07-26 주식회사유한양행 Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same
WO2016161109A1 (en) 2015-03-31 2016-10-06 The Regents Of The University Of California System and method for tunable patterning and assembly of particles via acoustophoresis
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6940479B2 (en) 2015-08-03 2021-09-29 ノバルティス アーゲー How to treat FGF21-related disorders
JP2018529729A (en) * 2015-10-01 2018-10-11 アムジエン・インコーポレーテツド Treatment of bile acid disorders
KR102668200B1 (en) 2015-10-28 2024-05-23 주식회사유한양행 Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same
KR102670157B1 (en) * 2015-10-28 2024-05-29 주식회사유한양행 Dual function proteins and pharmaceutical composition comprising the same
AU2016344134A1 (en) 2015-10-30 2018-05-31 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
JP6728352B2 (en) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド How to treat disorders related to bile acids
TW201731867A (en) 2015-12-02 2017-09-16 賽諾菲公司 FGF21 variants
SG11201807279QA (en) 2016-03-31 2018-09-27 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
CN107759697B (en) * 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 Method for producing fusion protein
CN106279437B (en) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CA3034275A1 (en) * 2016-08-22 2018-03-01 Elanco Us Inc. Bovine fibroblast growth factor 21 and ketosis in dairy cattle
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2018088838A1 (en) 2016-11-10 2018-05-17 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
WO2018115401A1 (en) 2016-12-22 2018-06-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
EP3612637A4 (en) 2017-04-21 2021-01-27 Yuhan Corporation Method for producing dual function proteins and its derivatives
CN107056925B (en) 2017-04-28 2022-01-14 中国科学院合肥物质科学研究院 Human FGF21 mutant, preparation method and application thereof
JP7476097B2 (en) * 2017-10-27 2024-04-30 スワール ライフ サイエンス エービー Secreted reporter peptides to optimize cell-based assays for analysis on immunoassay platforms
WO2019154189A1 (en) * 2018-02-08 2019-08-15 Sunshine Lake Pharma Co., Ltd. Fgf21 variant, fusion protein and application thereof
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
EP3817720A2 (en) 2018-07-03 2021-05-12 Bristol-Myers Squibb Company Fgf21 formulations
CN109836486B (en) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 Fibroblast growth factor 21 variants, fusion proteins thereof, and uses thereof
CN111662373B (en) * 2019-03-05 2024-05-14 广东东阳光药业股份有限公司 Polypeptide molecule and application thereof
CN111944055B (en) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 Fusion protein for treating metabolic diseases
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CN113583142A (en) * 2021-08-20 2021-11-02 赣江中药创新中心 Double-target fusion protein, coding gene, vector or host cell and application and expression and purification method thereof
WO2023035817A1 (en) * 2021-09-08 2023-03-16 北京志道生物科技有限公司 Fgf21 mutant protein and use thereof
EP4406968A1 (en) 2021-09-23 2024-07-31 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-klb antibodies and uses
AU2022361936A1 (en) 2021-10-13 2024-05-09 Akero Therapeutics, Inc. Pharmaceutical compositions of efruxifermin
WO2024059507A1 (en) 2022-09-12 2024-03-21 Akero Therapeutics, Inc. Fgf21 mutant polypeptides
CN118496383A (en) * 2023-06-02 2024-08-16 东北农业大学 Preparation of canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
CA1310924C (en) 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
ATE106249T1 (en) 1987-11-05 1994-06-15 Hybritech Inc POLYSACCHARIDE MODIFIED IMMUNOGLOBULINS WITH REDUCED IMMUNOGENIC POTENTIAL OR IMPROVED PHARMACOKINETICS.
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE135370T1 (en) 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5288855A (en) 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
JP3039802B2 (en) 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア Receptor for fibroblast growth factor
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
JP3501286B2 (en) 1989-12-22 2004-03-02 アプライド リサーチ システムズ，エーアールエス ホールディング ナームロゼ ベノートスハップ Methods for altering the expression characteristics of endogenous genes in certain cell lines or microorganisms
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
ATE243253T1 (en) 1990-07-06 2003-07-15 Rhone Poulenc Rorer Internat H RECEPTORS OF GROWTH FACTORS FROM FIBROBLASTS
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5217889A (en) 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5229501A (en) 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IL100219A0 (en) 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
ATE141958T1 (en) 1992-06-18 1996-09-15 Whittier Inst Diabetes & Endoc METHOD FOR DETECTING NEOPLASTIC DISEASES
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
GB9313210D0 (en) * 1993-06-25 1993-08-11 Sandoz Ltd Novel combinations
WO1994028122A1 (en) 1993-05-26 1994-12-08 Ontario Cancer Institute Transgenic mammals lacking expression of particular cd45 isoforms
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
ES2140359T1 (en) 1993-06-14 2000-03-01 Basf Ag PRECISE CONTROL OF GENETIC EXPRESSION IN EUCARIOTIC CELLS THROUGH PROMOTERS RESPONDING TO TETACICLINE.
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5469743A (en) * 1993-06-24 1995-11-28 Zorn; Roger H. Dynamic surface wave roll inspection device
ATE218893T1 (en) 1993-08-12 2002-06-15 Neurotech Sa BIOCOMPATIBLE IMMUNOISOLATION CAPSULES CONTAINING GENETICALLY MODIFIED CELLS
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5654166A (en) * 1994-11-09 1997-08-05 Kurth; Gerhard P. Process of preparing hormone-free bovine cartilage for dosage form
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE390933T1 (en) 1995-04-27 2008-04-15 Amgen Fremont Inc HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
MX9709156A (en) 1995-05-26 1998-03-31 Zeneca Ltd A gene switch comprising an ecdysone receptor.
KR19990022651A (en) 1995-06-07 1999-03-25 데이비드 엘. 버스테인 Rapamycin-Based Control of Biological Events
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
EP0832269A1 (en) 1995-06-07 1998-04-01 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
WO1997031898A1 (en) 1996-02-28 1997-09-04 Ariad Gene Therapeutics, Inc. Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
US6214795B1 (en) 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
KR20000062345A (en) 1996-12-26 2000-10-25 히라타 다다시 Novel peptide, novel DNA, and novel antibody
EP0861900A1 (en) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6150096A (en) * 1997-09-26 2000-11-21 Universite De Sherbrooke Molecular markers for the diagnosis of human diseases including Crohn's disease
IL136055A0 (en) 1997-11-25 2001-05-20 Genentech Inc Fibroblast growth factor -19
US6150098A (en) 1998-02-20 2000-11-21 Amgen Inc. Methods for identifying novel secreted mammalian polypeptides
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000027885A1 (en) 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Novel chimeric polypeptide
AU3224700A (en) 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
AU3755900A (en) 1999-03-15 2000-10-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2001018209A1 (en) 1999-09-10 2001-03-15 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
ES2335386T3 (en) 1999-11-18 2010-03-26 Novartis Vaccines And Diagnostics, Inc. GEN FGF-21 HUMAN AND GENE EXPRESSION PRODUCTS.
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1628101A (en) 1999-11-22 2001-06-04 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
US7108984B2 (en) 2000-01-12 2006-09-19 Mount Sinai School Of Medicine Methods of identifying modulators of the FGF receptor
US20020081663A1 (en) 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
WO2001049849A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf11
AU5056501A (en) 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
JP2002112772A (en) 2000-07-10 2002-04-16 Takeda Chem Ind Ltd New polypeptide and its dna
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20040018499A1 (en) 2001-06-06 2004-01-29 Lal Preeti G Extracellular messengers
JP2005500034A (en) 2001-06-20 2005-01-06 プロション バイオテク リミテッド Antibody that blocks activation of receptor protein tyrosine kinase, screening method thereof, and use thereof
EP1425304B9 (en) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf conjugates
AU2002322394A1 (en) 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
WO2003038054A2 (en) 2001-10-31 2003-05-08 New York University Structure-based design and synthesis of fgf inhibitors and fgf modulator compounds
US20050176631A1 (en) 2002-01-15 2005-08-11 Heuer Josef G. Method for reducing morbidity and mortality in critically ill patients
EP1332761A1 (en) 2002-01-31 2003-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Agonists of fibroblast growth factor receptors (FGFR)
DK1469878T3 (en) 2002-01-31 2011-07-18 Max Planck Gesellschaft FGFR agonists
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
JP2003334088A (en) 2002-05-22 2003-11-25 Pharma Design Inc HUMAN-DERIVED NEW Klotho-LIKE PROTEIN AND ITS GENE
WO2004022095A1 (en) 2002-09-04 2004-03-18 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
EP1578367A4 (en) 2002-11-01 2012-05-02 Genentech Inc Compositions and methods for the treatment of immune related diseases
US20060281130A1 (en) 2002-12-20 2006-12-14 Elisabeth Bock Metod of modulation of interaction between receptor and ligand
TWI300430B (en) * 2003-01-10 2008-09-01 Ritek Corp Optical recording medium dye and optical recording medium using thereof
AU2004206483B2 (en) * 2003-01-23 2008-06-26 Lg Electronics Inc. Recording medium with copy protection information formed in intermittent or alternate wobbled pits and apparatus and methods for forming, recording, and reproducing the recording medium
WO2004083381A2 (en) 2003-03-13 2004-09-30 Indiana University Advanced Research & Technology Institute Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants
JP2006240990A (en) 2003-05-15 2006-09-14 Kirin Brewery Co Ltd Klotho protein and anti-klotho protein antibody and use of them
MXPA05013564A (en) 2003-06-12 2006-03-09 Lilly Co Eli Fusion proteins.
CN1802386B (en) 2003-06-12 2010-12-15 伊莱利利公司 GLP-1 analog fusion proteins
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ATE506077T1 (en) 2003-10-16 2011-05-15 Imclone Llc FIBROBLAST GROWTH FACTOR 1 INHIBITORS AND TREATMENT METHODS THEREOF
KR20060135648A (en) 2003-12-10 2006-12-29 일라이 릴리 앤드 캄파니 Muteins of fibroblast growth factor 21
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
EP1727559A1 (en) 2004-01-26 2006-12-06 Eli Lilly And Company Use of fgf-21 and a thiazolidinedione for treating type 2 diabetes
US7887790B2 (en) * 2004-02-20 2011-02-15 Cornell Research Foundation, Inc. Polymers and polymer coatings
WO2005091944A2 (en) * 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
JP4505631B2 (en) 2004-03-31 2010-07-21 独立行政法人産業技術総合研究所 Heparin-binding protein with heparan sulfate sugar chain added, method for producing the same, and pharmaceutical composition containing the same
WO2005113606A2 (en) * 2004-05-13 2005-12-01 Eli Lilly And Company Fgf-21 fusion proteins
KR100854198B1 (en) * 2004-09-02 2008-08-26 일라이 릴리 앤드 캄파니 21 muteins of fibroblast growth factor 21
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
JP5948627B2 (en) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー Fibroblast growth factor (FGF) remodeling and carbohydrate pegylation
WO2006065582A2 (en) * 2004-12-14 2006-06-22 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
JP2006246823A (en) 2005-03-11 2006-09-21 Kyoto Univ Use of fgf21 as hematopoietic factor
WO2006130527A2 (en) 2005-05-31 2006-12-07 Novartis Ag Mutations and polymorphisms of fibroblast growth factor receptor 1
ES2336832T3 (en) 2005-07-22 2010-04-16 Five Prime Therapeutics, Inc. COMPOSITIONS AND PROCEDURES TO TREAT DISEASES WITH FGFR FUSION PROTEINS.
US7931902B2 (en) 2005-08-15 2011-04-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US7395962B2 (en) 2005-10-28 2008-07-08 United Parcel Service Of America, Inc. Pick up notice and method of using same
WO2007055789A2 (en) 2005-10-31 2007-05-18 Neose Technologies, Inc. Expression of soluble therapeutic proteins
WO2007056789A1 (en) 2005-11-16 2007-05-24 Dier Corporation As Trustee For The Reid Family Superannuation Trust New frame assemblies for security screens
WO2007100722A2 (en) 2006-02-28 2007-09-07 Trustees Of Boston University Methods to identify factors associated with muscle growth and uses thereof
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
JP2010505874A (en) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス Purification method for polypeptide conjugates
SG177225A1 (en) 2006-12-01 2012-01-30 Agency Science Tech & Res Cancer-related protein kinases
CN104163864B (en) 2007-03-30 2017-08-01 Ambrx公司 Through modifying the polypeptides of FGF 21 and its purposes
PE20090227A1 (en) 2007-04-02 2009-04-03 Genentech Inc PHARMACEUTICAL COMPOSITIONS INCLUDING ANTI-BETA-KLOTHO AGENTS
WO2008123625A1 (en) 2007-04-06 2008-10-16 National Institute Of Advanced Industrial Science And Technology Method for activating receptor by cofactor and method for utilizing ligand activity
US7537903B2 (en) 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
EP2152295B1 (en) 2007-05-08 2018-04-18 Tel HaShomer Medical Research Infrastructure and Services Ltd. Klotho protein and related compounds for the treatment of cancer
BRPI0812384A2 (en) 2007-05-22 2014-12-02 Novartis Ag TREATMENT, DIAGNOSTIC AND DISEASE TREATMENT METHODS ASSOCIATED WITH FGF21
JP5563818B2 (en) 2007-05-29 2014-07-30 北海道公立大学法人 札幌医科大学 Cancer therapeutic agent and cancer treatment method
WO2008151258A2 (en) 2007-06-04 2008-12-11 Neose Technologies, Inc. O-linked glycosylation using n-acetylglucosaminyl transferases
JP2010535781A (en) 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー Treatment for obesity
WO2009020602A2 (en) 2007-08-08 2009-02-12 Foster-Miller, Inc. Watercraft drogue system
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US20110015345A1 (en) 2008-03-19 2011-01-20 Ambrx, Inc. Modified FGF-23 Polypeptides and Their Uses
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
WO2010006214A1 (en) 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
BRPI0916904A2 (en) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polypeptides, ecd fgfr4 fusion molecules, pharmaceutical compositions, polynucleotide and methods of treating angiogenic disorder, patient cancer and patient macular degeneration and their uses
MX2011011815A (en) * 2009-05-05 2012-01-27 Amgen Inc Fgf21 mutants and uses thereof.
CN107188950B (en) * 2009-05-05 2021-09-28 安姆根有限公司 FGF21 mutant and application thereof

Also Published As

Publication number Publication date
CA2760196A1 (en) 2010-11-11
DK3248610T3 (en) 2024-01-15
TWI436776B (en) 2014-05-11
CN102655877A (en) 2012-09-05
US20120178685A1 (en) 2012-07-12
EP3248610A1 (en) 2017-11-29
CO6470863A2 (en) 2012-06-29
JP2012525844A (en) 2012-10-25
RS65153B1 (en) 2024-02-29
ES2969528T3 (en) 2024-05-21
WO2010129503A1 (en) 2010-11-11
LT3248610T (en) 2024-01-25
EA201171220A1 (en) 2012-05-30
JO3469B1 (en) 2020-07-05
PE20120358A1 (en) 2012-04-26
PT3248610T (en) 2024-02-01
US8795985B2 (en) 2014-08-05
EA021425B1 (en) 2015-06-30
HK1247134A1 (en) 2018-09-21
PH12015502433A1 (en) 2017-01-16
UY38740A (en) 2020-12-31
BRPI1011404B1 (en) 2022-05-03
AU2010246108A1 (en) 2011-11-24
UY32607A (en) 2010-12-31
FI3248610T3 (en) 2024-01-18
CN107188950B (en) 2021-09-28
EP3248610B1 (en) 2023-12-20
HRP20240135T1 (en) 2024-04-12
TW201105345A (en) 2011-02-16
IL215937A (en) 2015-11-30
KR101860572B1 (en) 2018-05-24
EP2427208A1 (en) 2012-03-14
EP4353247A2 (en) 2024-04-17
IL215937A0 (en) 2011-12-29
ES2632742T3 (en) 2017-09-15
KR20120068764A (en) 2012-06-27
CR20110639A (en) 2012-01-06
CA2760196C (en) 2019-02-26
JP5823954B2 (en) 2015-11-25
TWI560197B (en) 2016-12-01
US20100285131A1 (en) 2010-11-11
SI3248610T1 (en) 2024-03-29
SG10201402038WA (en) 2014-07-30
CN102655877B (en) 2017-04-05
MY156542A (en) 2016-02-26
US20120177646A1 (en) 2012-07-12
HUE065036T2 (en) 2024-04-28
AR076541A1 (en) 2011-06-22
US8188040B2 (en) 2012-05-29
EP2427208B1 (en) 2017-04-26
MA33716B1 (en) 2012-11-01
PH12015502433B1 (en) 2017-01-16
CL2011002768A1 (en) 2012-08-24
US8618053B2 (en) 2013-12-31
US8835385B2 (en) 2014-09-16
TW201446793A (en) 2014-12-16
KR20180014235A (en) 2018-02-07
PE20160718A1 (en) 2016-08-03
SG175861A1 (en) 2011-12-29
IL242377A (en) 2016-12-29
ZA201108371B (en) 2012-07-25
EP4353247A3 (en) 2024-07-17
PL3248610T3 (en) 2024-04-02
NZ596037A (en) 2013-10-25
AU2010246108B2 (en) 2014-10-23
BRPI1011404A2 (en) 2016-03-15
MX2011011709A (en) 2012-02-29
CN107188950A (en) 2017-09-22
US20120213779A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
HK1247134A1 (en) Fgf21 mutants and uses thereof
ZA201103356B (en) Fgf21 mutants and uses thereof
IL209395A0 (en) Fgf21 mutants and uses thereof
IL210804A (en) Benzylidenehydrazides and uses thereof
GB0916578D0 (en) Polypeptides and uses thereof
GB0808575D0 (en) Compilign and linking
ZA201109034B (en) Aminopyrrolidinone derivatives and uses thereof
GB0916576D0 (en) Polypeptides and uses thereof
EP2483292A4 (en) Variant lovd polypeptides and their uses
ZA201106702B (en) Sceletium extract and uses thereof
GB0921001D0 (en) Products and uses
ZA201103456B (en) Leukolectins and uses thereof
EP2291377A4 (en) Imidazopyrimidinones and uses thereof
GB0903299D0 (en) Composition and methods
PL2247601T3 (en) Thiazopyrimidinones and uses thereof
HK1178526A1 (en) Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof 8--7-
GB0912744D0 (en) Methods and uses
EP2408808A4 (en) Terminally-functionalized conjugates and uses thereof
ZA201008778B (en) Fgf21 mutants and uses thereof
GB0909792D0 (en) Composition and uses thereof
EP2291522A4 (en) Herg mutants and uses thereof
GB0808857D0 (en) Methdos and uses
GB0920904D0 (en) Uses and methods
GB0902351D0 (en) Bacteriophage and their uses
GB0810609D0 (en) Methods and uses